Canada
This article was added by the user . TheWorldNews is not responsible for the content of the platform.

Novavax to make COVID-19 vaccine shots in Canada

Vials with a sticker reading "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken Oct. 31, 2020.
Vials with a sticker reading "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken Oct. 31, 2020. Photo by Dado Ruvic /REUTERS

Novavax Inc said on Wednesday it will manufacture its COVID-19 vaccine in Canada after the country’s health regulator allowed its use in children aged between 12 and 17 years as a primary series of shots.

Production of test batches of the protein-based vaccine, Nuvaxovid, will begin at the Montreal manufacturing centre by early 2023, the company said.

As the Canadian national soccer teams head to their respective FIFA World Cups, Derek Van Diest is on the scene to cover all the action. Expect expert insights and analysis in your inbox daily throughout the tournaments, and weekly on Thursdays for the rest of the season.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

The agency’s approval was based on a late-stage study which showed the vaccine was effective against COVID-19 in children aged between 12 and 17 years.

Earlier this year, the Canadian health regulator had allowed the use of Novavax’s vaccine for primary series and as a booster in adults above 18 years of age.

Hurt by a global supply glut in COVID-19 vaccine and waning demand, Novavax cut its full-year revenue forecast last month to a range of $2 billion and $2.3 billion. Shots from rivals Pfizer/BioNtech and Moderna were approved last year for initial vaccination of adolescents in Canada, hurting the vaccine maker further.

Shares of the Maryland-based company rose 5% to $17.64 in early trade.